Due to the targeted inhibitory effect of the 33 peptide on α6β1, it is possible that the 33 peptide may exert an anti-tumor effect by mediating integrin α6β1to inhibit the PI3K-Akt pathway. This evidence concerns the gene AKT1 and neoplasm.